SOM Faculty Profile : Julie A Kreyenbuhl

Julie A Kreyenbuhl

Julie A Kreyenbuhl Pharm.D., Ph.D.

Academic Title: Associate Professor

Primary Appointment: Psychiatry

jkreyenb@psych.umaryland.edu

Location: VAMC 6A

Phone: (410) 605-7466

Fax: (410) 605-7739

Personal History

Julie Kreyenbuhl, Pharm.D., Ph.D. is an Assistant Professor in the Department of Psychiatry and a research investigator with the VA Capitol Health Care Network (VISN 5) Mental Illness Research, Education and Clinical Center (MIRECC). She completed her clinical pharmacy training at Mercer University Southern School of Pharmacy in 1993 and received a PhD in Pharmaceutical Health Services Research from the University of Maryland School of Pharmacy in 1999. She completed a post-doctoral fellowship at the Maryland Psychiatric Research Center in 2000.

Research Interests

Dr. Kreyenbuhl's primary research focus is the pharmacoepidemiology of schizophrenia, which involves examining prescription patterns and outcomes of pharmacologic treatments in typical clinical practice settings. In 2003, she was awarded a 5-year NIMH K01 Research Career Award to study the roles of the clinician, patient and family in the process of prescription decision-making related to the use of complex, multi-drug regimens ('polypharmacy') in schizophrenia, with a particular focus on the use of antipsychotic polypharmacy. She has contributed to the development of the most recent updates of the Schizophrenia Patient Outcomes Research Team (PORT) Treatment Recommendations and the American Psychiatric Association’s Practice Guideline for the Treatment of Patients with Schizophrenia.

Dr. Kreyenbuhl is also interested in the patterns and outcomes of use of medications for somatic conditions such as Type 2 diabetes in this population. In 2005, she received a NARSAD Young Investigator Award to investigate whether patients with schizophrenia and Type 2 diabetes exhibit differential rates of adherence to hypoglycemic medications versus antipsychotic medications, and whether patients with schizophrenia exhibit differential rates of adherence to hypoglycemic medications compared to patients without a psychiatric disorder. She has also examined the management of risk for cardiovascular disease among patients with severe mental illnesses and Type 2 diabetes and is interested in the metabolic adverse effects of second-generation antipsychotic agents in these patients.

Publications

Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J; American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;161(2 Suppl):1-56.

Lehman AF, Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB, Goldberg R, Green-Paden LD, Tenhula WN, Boerescu D, Tek C, Sandson N. The Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2003. Schizophrenia Bulletin 2004; 30(2):193-217.

Sokal J, Messias E, Dickerson FB, Kreyenbuhl J, Brown CH, Goldberg RW, Dixon LB. Co-morbidity of medical illnesses among adults with serious mental illness who are receiving community psychiatric services. Journal of Nervous and Mental Disease 2004; 192(6): 421-427.

Lucksted A, McGuire C, Postrado L, Kreyenbuhl J, Dixon LB. Specifying cigarette smoking and quitting among people with serious mental illness. The American Journal on Addictions / American Academy of Psychiatrists in Alcoholism and Addictions 2004; 13 (2):128-138.

Dixon L, Kreyenbuhl J, Dickerson F, Donner T, Brown C, Wohlheiter K, Postrado L, Goldberg R, Messias E, Fang L. A comparison of Type 2 diabetes outcomes among individuals with and without severe mental illnesses. Psychiatric Services 2004; 55: 892-900.

Dickerson FB, Brown CH, Kreyenbuhl J, Goldberg RW, Fang L, Dixon LB. Sexual and reproductive behaviors among persons with serious mental illness. Psychiatric Services 2004 55: 1299-1301.

Himelhoch S, Lehman AF, Kreyenbuhl J, Daumit G, Brown C, Dixon L. Prevalence of COPD among those with serious mental illness. American Journal of Psychiatry 2004; 161(12):2317-9.

Dickerson FB, Goldberg RW, Brown CH, Kreyenbuhl JA, Wohlheiter K, Fang L, Medoff D, Dixon LB. Diabetes knowledge among persons with serious mental illness and type 2 diabetes. Psychosomatics 2005; 46(5):418-24.

Daumit GL, Goldberg RW, Anthony C, Dickerson F, Brown CH, Kreyenbuhl J, Wohlheiter K, Dixon LB. Physical activity patterns in adults with severe mental illness. Journal of Nervous and Mental Disease 2005; 193: 641-646.

Goldberg RW, Himelhoch S, Kreyenbuhl J, Dickerson FB, Hackman A, Fang L, Brown CH, Wohlheiter KA, Dixon LB. Predictors of HIV and hepatitis testing and related service utilization among individuals with serious mental illness. Psychosomatics 2005; 46(6): 573-577.

Dickerson FB, Brown CH, Kreyenbuhl JA, Fang L, Goldberg RW, Wohlheiter K, Dixon LB. Obesity among individuals with serious mental illness. Acta Psychiatr Scand 2006; 113: 306-313.

Hackman AL, Goldberg RW, Brown CH, Fang L, Dickerson FB, Wohlheiter K, Medoff DR, Kreyenbuhl JA, Dixon L. The use of emergency department services for somatic reasons by people with serious mental illness. Psychiatric Services 2006; 57:563-566.

Kreyenbuhl J, Dickerson FB, Medoff DR, Brown CH, Goldberg RW, Fang L, Wohlheiter K, Mittal LP, Dixon LB. Extent and management of cardiovascular risk factors in patients with Type 2 diabetes and serious mental illness. Journal of Nervous and Mental Disease 2006; 194 (6): 404-410.

Kreyenbuhl J, Valenstein M, McCarthy JF, Ganoczy D, Blow FC. Long-term combination antipsychotic treatment in VA patients with schizophrenia. Schizophrenia Research 2006 May; 84(1):90-99

Faculty members: Click here to update your contact information and create a profile.